Does the Treatment of Both Hypertension and Cardiac Hypertrophy Not Only Prevent But Also Treat Acute Myocardial Infarction?

Asanuma, Hiroshi; Kitakaze, Masafumi

doi:10.1253/circj.cj-11-0292

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, one or the combination of these conditions may blunt the actions of IP in the clinical setting. 12 Recently, Tamura et al demonstrated that HI in combination with target temperature management is a safe and feasible procedure for patients with post-cardiac arrest syndrome (PCAS) and thus can be considered as a novel therapeutic approach for PCAS patients. 13 Unfortunately, this study was not powered to test efficacy, because of it was exploratory, aimed at assessing the probability of…”

Section: Article P 940mentioning

confidence: 99%

Translational Study of Hydrogen Gas Inhalation as Adjuncts to Reperfusion Therapy for Acute Myocardial Infarction

Asanuma

Kitakaze

2017

Circ J

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Article P 940mentioning

confidence: 99%

Translational Study of Hydrogen Gas Inhalation as Adjuncts to Reperfusion Therapy for Acute Myocardial Infarction

Asanuma

Kitakaze

2017

Circ J

Self Cite

View full text Add to dashboard Cite

show abstract

Emerging role of VCP/p97 in cardiovascular diseases: novel insights and therapeutic opportunities

Shu

Peng

Hang

et al. 2021

Biochemical Society Transactions

View full text Add to dashboard Cite

Valosin-containing protein (VCP/p97) is a member of the conserved type II AAA+ (ATPases associated with diverse cellular activities) family of proteins with multiple biological functions, especially in protein homeostasis. Mutations in VCP/p97 are reportedly related to unique autosomal dominant diseases, which may worsen cardiac function. Although the structure of VCP/p97 has been clearly characterized, with reports of high abundance in the heart, research focusing on the molecular mechanisms underpinning the roles of VCP/p97 in the cardiovascular system has been recently undertaken over the past decades. Recent studies have shown that VCP/p97 deficiency affects myocardial fibers and induces heart failure, while overexpression of VCP/p97 eliminates ischemia/reperfusion injury and relieves pathological cardiac hypertrophy caused by cardiac pressure overload, which is related to changes in the mitochondria and calcium overload. However, certain studies have drawn opposing conclusions, including the mitigation of ischemia/reperfusion injury via inhibition of VCP/p97 ATPase activity. Nevertheless, these emerging studies shed light on the role of VCP/p97 and its therapeutic potential in cardiovascular diseases. In other words, VCP/p97 may be involved in the development of cardiovascular disease, and is anticipated to be a new therapeutic target. This review summarizes current findings regarding VCP/p97 in the cardiovascular system for the first time, and discusses the role of VCP/p97 in cardiovascular disease.

show abstract

Does the Treatment of Both Hypertension and Cardiac Hypertrophy Not Only Prevent But Also Treat Acute Myocardial Infarction?

Cited by 2 publications

References 17 publications

Translational Study of Hydrogen Gas Inhalation as Adjuncts to Reperfusion Therapy for Acute Myocardial Infarction

Translational Study of Hydrogen Gas Inhalation as Adjuncts to Reperfusion Therapy for Acute Myocardial Infarction

Emerging role of VCP/p97 in cardiovascular diseases: novel insights and therapeutic opportunities

Contact Info

Product

Resources

About